The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Quest’s two AD-Detect blood-based tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer’s disease pathology in ...

GRAIL's financial position is reinforced by $435 million in new funding, including strategic backing from Samsung for ...

Heal Squad' podcast host Maria Menounos, whose pancreatic cancer was discovered early enough to be treated, says, "If it ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...

Guardant Health received FDA approval for its Guardant360 CDx blood test as a companion diagnostic for Eli Lilly’s Inluriyo, targeting advanced breast cancer patients with ESR1 mutations. This ...

The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to help rule out Alzheimer’s disease in ...

The company noted that if PAMA cuts go into effect at the beginning of next year as scheduled, they would negatively impact its 2026 revenues by around $100 million.

Laboratory operator Quest Diagnostics raised its full-year forecast for profit and revenue on Tuesday, banking on robust demand for its diagnostic tests, after posting strong results for the third ...

Quest Diagnostics Incorporated stock reached an all-time high of 191.87 USD, marking a significant milestone for the company. According to InvestingPro data, the company maintains a "GREAT" financial ...